Advanced Solid Tumors, Cervical Cancer, Cholangiocarcinoma, Hematologic Neoplasms, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Ovarian Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, TNBC - Triple-Negative Breast Cancer
Conditions
Brief summary
The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.
Interventions
BIOLOGICALtebotelimab 1 mg
1 mg IV every other week
BIOLOGICALtebotelimab 3 mg
3 mg IV every other week
BIOLOGICALtebotelimab 10 mg
10 mg IV every other week
BIOLOGICALtebotelimab 30 mg
30 mg IV every other week
BIOLOGICALtebotelimab 120 mg
120 mg IV every other week
BIOLOGICALtebotelimab 300 mg
300 mg IV every other wee
BIOLOGICALtebotelimab 400 mg
400 mg IV every other wee
BIOLOGICALtebotelimab 600 mg
600 mg IV every other week
BIOLOGICALtebotelimab 800 mg
800 mg IV every other week
BIOLOGICALtebotelimab 1200 mg
1200 mg IV every other week
BIOLOGICALmargetuximab
15 mg/kg IV every 3 weeks
Sponsors
MacroGenics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven, locally advanced unresectable or metastatic solid tumors (or hematologic malignancies, Cohort Expansion only) for whom no approved therapy with demonstrated clinical benefit is available or standard treatment was declined. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy ≥ 12 weeks * Measurable disease * Tissue specimen available for retrospective analysis of PD-1, PD-L1, LAG-3, and MHC-II expression * Acceptable laboratory parameters HER2+ Cohort: \- Locally advanced or metastatic HER2+ locally advanced or metastatic solid tumors, regardless of organ of origin. i. The cancer must have progressed following standard therapy, or has progressed during or after HER2-directed therapy if approved and available for patients with HER2+ breast, gastric, or gastroesophageal junction cancer. ii. History of HER2 positivity defined as 3+ by IHC or 2+ by Immunohistochemistry (IHC) in combination with in situ hybridization (ISH) positivity most recent tumor biopsy. * All patients in the HER2+ cohort must be willing to provide consent for a baseline and on-treatment tumor biopsy during the screening period and within 14 days prior to Cycle 3 Day 1. Exceptions may be made based on a medical contraindication at the discretion of the Sponsor's Medical Monitor. This requirement will be discontinued after an adequate number of samples are collected, as determined by the Sponsor.
Exclusion criteria
* Symptomatic central nervous system (CNS) metastases or primary CNS lymphoma * History of allogeneic bone marrow, stem-cell, or solid organ transplant * History of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past 2 years), and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing. * Treatment with any systemic chemotherapy within 3 weeks prior to the initiation of study drug; treatment with biologics or investigational therapy within the 4 weeks prior to the initiation of study drug. * Major surgery within 4 weeks prior to the initiation of study drug. * Prior treatment with combination of monoclonal antibodies against PD-1 and LAG-3 (Cohort Expansion only). * Treatment with radiation therapy within 2 weeks prior to the initiation of study drug. * Clinically significant cardiovascular disease. * QTcF prolongation \> 480 milliseconds * HER2+ cohort: left ventricular ejection fraction less than 50% * Clinically significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation. * Active pneumonitis or history of non-infectious pneumonitis. * Clinically significant gastrointestinal disorders. * Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. * Known history of positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome. * Known history of hepatitis B (except in hepatocellular carcinoma) or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction (PCR) * Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed * Dementia or altered mental status that would preclude understanding and rendering of informed consent * Confirmed or presumed COVID-19/SARS-CoV-2 infection. While SARS-CoV-2 testing is not mandatory for study entry, testing should follow local clinical practice guidelines/standards. Patients with a positive test result for SARS-CoV-2 infection, known asymptomatic infection, or presumed infection are excluded. Patients may be considered eligible after a resolved SARS-CoV-2 infection once he or she remains afebrile for at least 72 hours and after other SARS-CoV-2-related symptoms have fully recovered to baseline for a minimum of 72 hours.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy) | up to 24 months | Safety Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit. |
| Number of participants with Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (tebotelimab plus margetuximab) | up to 24 months | Safety |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to reach maximum (peak) plasma concentration (Tmax) of tebotelimab and tebotelimab plus margetuximab | At the end of infusion on Study Days 1, 15, 29 and 43 in Cycles 1 and 2 and on Study Day 1 for all subsequent cycles until treatment discontinuation, up to 2 years | Tmax |
| Trough plasma concentration (Ctrough) of tebotelimab | Study Days 1, 15, 29, 43 in Cycles 1 and 2 and Day 1 of each subsequent cycle s until treatment discontinuation, up to 2 years | Ctrough |
| Total body clearance of the drug from plasma (CL) of tebotelimab | Cycle 1 Day 1 out to Cycle 1 Day 15 | CL |
| Apparent volume of distribution at steady state (Vss) of tebotelimab | Cycle 1 Day 1 out to Cycle 1 Day 15 | Vss |
| Terminal half-life (t1/2) of tebotelimab | Cycle 1 Day 1 out to Cycle 1 Day 15 | t1/2 |
| Area Under the Plasma Concentration versus Time Curve (AUC) of tebotelimab | From Day 1 to Day 15 after the first and second doses | AUC |
| Objective response rate (ORR) | Throughout the study, up to 4 years. | ORR is the percentage of participants who have a complete response or a partial response to treatment. |
| Median Duration of response (DoR) | Throughout the study, up to 4 years. | DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first. Median DoR is the time when 50% of responders are still in response. |
| Progression-free survival (PFS) | Throughout the study, up to 4 years. | PFS is defined as the time from the first dose date to the date of first documented PD or death from any cause, whichever occurs first. Median PFS is the time when 50% of participants remain free of PD or death. |
| Median Overall survival (OS) | Throughout the study, up to 4 years. | OS is defined as the time from the first dose date to the date of death from any cause. Median OS is the time when 50% of participants are still alive. |
| Number of patients with anti-drug antibody | Study Day 1, 15, 29, 57, 85, 113, then every 56 days up to 2 years Tebotelimab plus margetuximab: Day 1, 22, 43, and then every 6 weeks until treatment discontinuation | immunogenicity |
| Maximum Plasma Concentration (Cmax) of tebotelimab and tebotelimab plus margetuximab | At the end of infusion on Study Days 1, 15, 29 and 43 in Cycles 1 and 2 and on Study Day 1 for all subsequent cycles until treatment discontinuation, up to 2 years | Cmax |
Countries
Australia, Bulgaria, Hong Kong, Poland, Spain, Thailand, Ukraine, United States
Outcome results
None listed